SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Staples JE, Gershman M, Fischer M.Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep2010;59:127.
  • 2
    Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C.Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.Am J Trop Med Hyg1999;60:104550.
  • 3
    Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, et al.Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.Am J Trop Med Hyg2002;66:53341.
  • 4
    Vaccinations in the immunocompromised person: guidelines for the patient taking immunosuppressant, steroids and the new biologic therapies. London: The British Society for Rheumatology;2002.
  • 5
    Anon.Le calendrier des vaccinations et les recommandations vaccinales 2012 selon l'avis du Haut Conseil de la santé publique.Bull Epidemiol Hebd2012;14:16188.
  • 6
    Pacanowski J, Lacombe K, Campa P, Dabrowska M, Poveda JD, Meynard JL, et al.Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients.J Acquir Immune Defic Syndr2012;59:3607.
  • 7
    Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, et al.Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.Clin Infect Dis2009;48:65966.
  • 8
    Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, et al.Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.Trans R Soc Trop Med Hyg2012;106:43744.
  • 9
    US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.2007. URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
  • 10
    Niedrig M, Lademann M, Emmerich P, Lafrenz M.Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA.Trop Med Int Health1999;4:86771.
  • 11
    Miettinen OS.Estimation of relative risk from individually matched series.Biometrics1970;26:7586.
  • 12
    Camacho LA, de Aguiar SG, Freire Mda S, Leal Mda L, do Nascimento JP, Iguchi T, et al.Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.Rev Saude Publica2005;39:41320.
  • 13
    Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al.Adverse event reports following yellow fever vaccination.Vaccine2008;26:607782.
  • 14
    Tattevin P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C, et al.Yellow fever vaccine is safe and effective in HIV-infected patients.AIDS2004;18:8257.
  • 15
    Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML.Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases.Clin Infect Dis2000;31:E78.
  • 16
    Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S.Vaccination in Brazilian HIV-infected adults: a cross-sectional study.AIDS Patient Care STDS2008;22:6570.
  • 17
    Pistone T, Verdiere CH, Receveur MC, Ezzedine K, Lafon ME, Malvy D.Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.Curr HIV Res2010;8:4616.
  • 18
    Azevedo LS, Lasmar EP, Contieri FL, Boin I, Percegona L, Saber LT, et al.Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study.Transpl Infect Dis2012;14:23741.
  • 19
    Mota LM, Oliveira AC, Lima RA, Santos-Neto LL, Tauil PL.Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases.Rev Soc Bras Med Trop2009;42:237. In Portuguese.
  • 20
    Scheinberg M, Guedes-Barbosa LS, Mangueira C, Rosseto EA, Mota L, Oliveira AC, et al.Yellow fever revaccination during infliximab therapy.Arthritis Care Res (Hoboken)2010;62:8968.
  • 21
    Kengsakul K, Sathirapongsasuti K, Punyagupta S.Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.J Med Assoc Thai2002;85:1314.
  • 22
    Pirofski LA, Casadevall A.Use of licensed vaccines for active immunization of the immunocompromised host.Clin Microbiol Rev1998;11:126.
  • 23
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al.Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.Arthritis Care Res (Hoboken)2011;63:10627.
  • 24
    Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, et al.Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants.Bull World Health Organ2009;87:50511.
  • 25
    Banovic T, Yanilla M, Simmons R, Robertson I, Schroder WA, Raffelt NC, et al.Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression.J Infect Dis2011;204:1893901.
  • 26
    Geiger R, Fink FM, Solder B, Sailer M, Enders G.Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission.J Med Virol1995;47:4424.
  • 27
    Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A, et al.Varicella vaccination in a child with acute lymphoblastic leukaemia.Lancet2007;369:1232.
  • 28
    Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C.Use of oral corticosteroids in the United Kingdom.QJM2000;93:10511.
  • 29
    Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, et al.An inactivated cell-culture vaccine against yellow fever.N Engl J Med2011;364:132633.